Phase I study of Gypenosides to treat optic neuritis

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16009216

Enrollment

Unknown

Registered

2016-09-17

Start date

2016-09-15

Completion date

Unknown

Last updated

2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic neuritis

Interventions

1:Oral Gypenoside

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged more than 18 years old; 2. Chinese patients diagnosed with optic neuritis.

Exclusion criteria

Exclusion criteria: 1. ischemic, hereditary, toxic, traumatic, radiation, compressive, or infectious optic neuropathy; 2. optic neuroretinitis or optic perineuritis; 3. pre-existing MS or NMO prior to the first onset of optic neuritis; 4. other organic eye diseases and brain lesions that significantly affected visual function, such as cataracts, retinal detachment, and pituitary adenoma; and 5 lack of follow-up.

Design outcomes

Primary

Measure	Time frame
side effect;	—

Countries

China

Contacts

Public ContactYi Du

The First Affiliated Hospital of Guangxi Medical University

duyinapoleon@gmail.com+86 0771-5356507

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026